Cargando…
Robustness of outcomes in trials evaluating sodium–glucose co‐transporter 2 inhibitors for heart failure
AIMS: Recent trials have evaluated sodium–glucose co‐transporter 2 inhibitors in patients with heart failure (HF). We sought to assess the robustness of findings from these trials using the fragility index (FI). METHODS AND RESULTS: Fragility index is defined as the minimum number of patients that m...
Autores principales: | Usman, Muhammad Shariq, Khan, Muhammad Shahzeb, Fonarow, Gregg C., Greene, Stephen J., Friede, Tim, Vaduganathan, Muthiah, Filippatos, Gerasimos, Coats, Andrew J. Stewart, Anker, Stefan D., Butler, Javed |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934993/ https://www.ncbi.nlm.nih.gov/pubmed/35029056 http://dx.doi.org/10.1002/ehf2.13785 |
Ejemplares similares
-
Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta‐analysis
por: Butler, Javed, et al.
Publicado: (2020) -
Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction
por: Tomasoni, Daniela, et al.
Publicado: (2022) -
What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2020) -
Reporting and interpretation of subgroup analyses in heart failure randomized controlled trials
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2020) -
Discontinuation and non‐publication of heart failure randomized controlled trials: a call to publish all trial results
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2020)